Thomas F Gajewski

List of Publications by Year
in descending order

144 papers	40,656 citations	8749 75 h-index	14736 127 g-index
149 all docs	149 docs citations	149 times ranked	43899 citing authors

#	Article	IF	Citations
1	Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology, 2013, 14, 1014-1022.	7.0	3,109
2	Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates antiâ€“PD-L1 efficacy. Science, 2015, 350, 1084-1089.	6.0	2,782
3	Melanoma-intrinsic Î²-catenin signalling prevents anti-tumour immunity. Nature, 2015, 523, 231-235.	13.7	2,130
4	The commensal microbiome is associated with antiâ€“PD-1 efficacy in metastatic melanoma patients. Science, 2018, 359, 104-108.	6.0	2,027
5	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell, 2017, 171, 934-949.e16.	13.5	1,515
6	STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity, 2014, 41, 843-852.	6.6	1,468
7	Up-Regulation of PD-L1, IDO, and T _{regs} in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells. Science Translational Medicine, 2013, 5, 200ra116.	5.8	1,447
8	STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors. Immunity, 2014, 41, 830-842.	6.6	1,325
9	Loss of PTEN Promotes Resistance to T Cellâ€“Mediated Immunotherapy. Cancer Discovery, 2016, 6, 202-216.	7.7	1,158
10	Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Reports, 2015, 11, 1018-1030.	2.9	1,083
11	Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell, 2017, 31, 711-723.e4.	7.7	1,011
12	Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8Î±+ dendritic cells. Journal of Experimental Medicine, 2011, 208, 2005-2016.	4.2	959
13	Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment. Cancer Research, 2009, 69, 3077-3085.	0.4	911
14	Helper T Cell Differentiation Is Controlled by the Cell Cycle. Immunity, 1998, 9, 229-237.	6.6	786
15	PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells. Cancer Research, 2004, 64, 1140-1145.	0.4	679
16	The immune score as a new possible approach for the classification of cancer. Journal of Translational Medicine, 2012, 10, 1.	1.8	656
17	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncology, The, 2019, 20, 1083-1097.	5.1	611
18	Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. Journal of Clinical Oncology, 2013, 31, 3182-3190.	0.8	530

#	Article	IF	Citations
19	The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science, 2018, 359, 1366-1370.	6.0	525
20	Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunology, Immunotherapy, 2005, 54, 307-314.	2.0	509
21	Impact of oncogenic pathways on evasion of antitumour immune responses. Nature Reviews Cancer, 2018, 18, 139-147.	12.8	506
22	Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. , 2014, 2, 3.		460
23	Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2018, 36, 1611-1618.	0.8	448
24	WNT/Î²-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clinical Cancer Research, 2019, 25, 3074-3083.	3.2	435
25	Innate Immune Recognition of Cancer. Annual Review of Immunology, 2015, 33, 445-474.	9.5	431
26	Immune resistance orchestrated by the tumor microenvironment. Immunological Reviews, 2006, 213, 131-145.	2.8	409
27	The Next Hurdle in Cancer Immunotherapy: Overcoming the Nonâ€"T-Cellâ€"Inflamed Tumor Microenvironment. Seminars in Oncology, 2015, 42, 663-671.	0.8	388
28	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. JAMA - Journal of the American Medical Association, 2014, 311, 2397.	3.8	359
29	PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood, 2009, 114, 1545-1552.	0.6	354
30	Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Current Opinion in Immunology, 2013, 25, 268-276.	2.4	352
31	Apoptosis Meets Signal Transduction: Elimination of a BAD Influence. Cell, 1996, 87, 589-592.	13.5	341
32	A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. European Journal of Immunology, 1994, 24, 3038-3043.	1.6	339
33	Density of immunogenic antigens does not explain the presence or absence of the T-cellâ€"inflamed tumor microenvironment in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7759-E7768.	3.3	328
34	The host STING pathway at the interface of cancer and immunity. Journal of Clinical Investigation, 2016, 126, 2404-2411.	3.9	327
35	Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8⁺ T cells. European Journal of Immunology, 2008, 38, 2438-2450.	1.6	312
36	Molecular Drivers of the Nonâ€"T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunology Research, 2016, 4, 563-568.	1.6	293

#	Article	IF	Citations
37	Glucose Availability Regulates IFN-Î³ Production and p70S6 Kinase Activation in CD8+ Effector T Cells. Journal of Immunology, 2005, 174, 4670-4677.	0.4	292
38	Innate immune signaling and regulation in cancer immunotherapy. Cell Research, 2017, 27, 96-108.	5.7	291
39	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responsesin vitro. International Journal of Cancer, 2006, 119, 317-327.	2.3	276
40	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). Journal of Clinical Oncology, 2018, 36, 3223-3230.	0.8	267
41	T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-Î±. Nature Immunology, 2006, 7, 1166-1173.	7.0	252
42	Costimulatory and coinhibitory receptors in antiâ€tumor immunity. Immunological Reviews, 2009, 229, 126-144.	2.8	246
43	First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2017, 23, 3269-3276.	3.2	244
44	Immune Suppression in the Tumor Microenvironment. Journal of Immunotherapy, 2006, 29, 233-240.	1.2	242
45	Targeting the Tumor Microenvironment with Interferon-Î² Bridges Innate and Adaptive Immune Responses. Cancer Cell, 2014, 25, 37-48.	7.7	236
46	Gene Signature in Melanoma Associated With Clinical Activity. Cancer Journal (Sudbury, Mass), 2010, 16, 399-403.	1.0	232
47	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncology, The, 2014, 15, 954-965.	5.1	225
48	Exploring the emerging role of the microbiome in cancer immunotherapy. , 2019, 7, 108.		217
49	Increasing Tumor Antigen Expression Overcomes â€œIgnoranceâ€• to Solid Tumors via Crosspresentation by Bone Marrow-Derived Stromal Cells. Immunity, 2002, 17, 737-747.	6.6	216
50	Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2017, 1036, 19-31.	0.8	212
51	Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment. Clinical Cancer Research, 2007, 13, 5256-5261.	3.2	210
52	Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clinical Cancer Research, 2019, 25, 4202-4210.	3.2	207
53	STING pathway agonism as a cancer therapeutic. Immunological Reviews, 2019, 290, 24-38.	2.8	204
54	The STING pathway and the T cell-inflamed tumor microenvironment. Trends in Immunology, 2015, 36, 250-256.	2.9	190

#	Article	IF	Citations
55	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews Clinical Oncology, 2013, 10, 588-598.	12.5	177
56	Allogeneic Stem-Cell Transplantation of Renal Cell Cancer After Nonmyeloablative Chemotherapy: Feasibility, Engraftment, and Clinical Results. Journal of Clinical Oncology, 2002, 20, 2017-2024.	0.8	169
57	Cancer and the Microbiomeâ€"Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology, 2021, 160, 600-613.	0.6	167
58	B7-1 Engagement of Cytotoxic T Lymphocyte Antigen 4 Inhibits T Cell Activation in the Absence of CD28. Journal of Experimental Medicine, 1998, 188, 205-210.	4.2	160
59	Lymphatic vessels regulate immune microenvironments in human and murine melanoma. Journal of Clinical Investigation, 2016, 126, 3389-3402.	3.9	157
60	The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. Journal of Experimental Medicine, 2017, 214, 381-400.	4.2	154
61	Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma. Journal of Clinical Oncology, 2003, 21, 2342-2348.	0.8	148
62	Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clinical Cancer Research, 2015, 21, 4774-4779.	3.2	145
63	Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Current Opinion in Immunology, 2011, 23, 286-292.	2.4	134
64	B7DC/PDL2 Promotes Tumor Immunity by a PD-1â€"independent Mechanism. Journal of Experimental Medicine, 2003, 197, 1721-1730.	4.2	130
65	Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunology Research, 2018, 6, 14-24.	1.6	129
66	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research, 2015, 21, 2289-2296.	3.2	128
67	Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites. Cancer Immunology, Immunotherapy, 2006, 55, 1185-1197.	2.0	127
68	Tumor-intrinsic oncogene pathways mediating immune avoidance. OncoImmunology, 2016, 5, e1086862.	2.1	120
69	Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA. Journal of Immunology, 2016, 196, 3191-3198.	0.4	107
70	Molecular regulation of Tâ€cell anergy. EMBO Reports, 2008, 9, 50-55.	2.0	101
71	Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells. Journal of Immunology, 2003, 171, 4574-4581.	0.4	99
72	CARMA1 Controls an Early Checkpoint in the Thymic Development of FoxP3+ Regulatory T Cells. Journal of Immunology, 2009, 182, 6736-6743.	0.4	99

#	Article	IF	Citations
73	Secondary resistance to immunotherapy associated with Î²-catenin pathway activation or PTEN loss in metastatic melanoma. , 2019, 7, 295.		98
74	NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. Journal of Immunology, 2016, 197, 953-961.	0.4	93
75	Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. Journal of Experimental Medicine, 2012, 209, 2157-2163.	4.2	91
76	Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment. Clinical Cancer Research, 2006, 12, 2326s-2330s.	3.2	85
77	Negative Regulation of T-Cell Function by PD-1. Critical Reviews in Immunology, 2004, 24, 229-238.	1.0	82
78	Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-Î³-signaling mutant cancer cells. Nature Communications, 2020, 11, 602.	5.8	81
79	Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma. Clinical Cancer Research, 2008, 14, 3156-3167.	3.2	79
80	Therapeutic Activity of High-Dose Intratumoral IFN-Î² Requires Direct Effect on the Tumor Vasculature. Journal of Immunology, 2014, 193, 4254-4260.	0.4	79
81	Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection. Journal of Immunology, 2006, 177, 4521-4529.	0.4	75
82	Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). Journal of Translational Medicine, 2012, 10, 246.	1.8	74
83	Cancer immunotherapy. Molecular Oncology, 2012, 6, 242-250.	2.1	71
84	Mechanisms of Tumor Cellâ€“Intrinsic Immune Evasion. Annual Review of Cancer Biology, 2018, 2, 213-228.	2.3	65
85	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
86	T cell-NF-Î°B activation is required for tumor control in vivo. , 2015, 3, 1.		64
87	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
88	Rational combinations of immunotherapeutics that target discrete pathways. , 2013, 1, 16.		62
89	Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma. Clinical Cancer Research, 2005, 11, 7861-7865.	3.2	61
90	CD40 ligation reverses T cell tolerance in acute myeloid leukemia. Journal of Clinical Investigation, 2013, 123, 1999-2010.	3.9	60

#	Article	IF	Citations
91	Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. , 1999, 80, 324-333.		57
92	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. OncoImmunology, 2016, 5, e1240857.	2.1	56
93	Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. , 2021, 9, e003521.		56
94	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. European Journal of Cancer, 2020, 127, 52-66.	1.3	52
95	Î²-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cellsâ€"Phospholipase C-Î³1 Phosphorylation. Journal of Immunology, 2011, 186, 784-790.	0.4	50
96	New perspectives on type I IFNs in cancer. Cytokine and Growth Factor Reviews, 2015, 26, 175-178.	3.2	50
97	Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A. European Journal of Immunology, 1995, 25, 1836-1842.	1.6	46
98	Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. , 2018, 6, 73.		46
99	Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation. Journal of Immunology, 2012, 188, 2630-2642.	0.4	45
100	Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunology, Immunotherapy, 2012, 61, 1343-1347.	2.0	44
101	Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. , 1999, 81, 428-437.		42
102	COVIDOSE: A Phase II Clinical Trial of Lowâ€Dose Tocilizumab in the Treatment of Noncritical COVIDâ€19 Pneumonia. Clinical Pharmacology and Therapeutics, 2021, 109, 688-696.	2.3	42
103	Immunotherapy with a sting. Science, 2020, 369, 921-922.	6.0	41
104	Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Molecular Immunology, 2013, 55, 283-291.	1.0	37
105	High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions. Cancer Immunology Research, 2019, 7, 50-61.	1.6	36
106	Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine, 2016, 77, 245-247.	1.4	35
107	Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Molecular Cancer Therapeutics, 2018, 17, 2399-2411.	1.9	34
108	A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. , 2013, 1, 8.		30

#	Article	IF	Citations
109	Gene Array and Protein Expression Profiles Suggest Post-transcriptional Regulation during CD8+ T Cell Differentiation. Journal of Biological Chemistry, 2003, 278, 17044-17052.	1.6	29
110	Induction of Cytotoxic Granules in Human Memory CD8+ T Cell Subsets Requires Cell Cycle Progression. Journal of Immunology, 2006, 177, 1981-1987.	0.4	29
111	Molecular Profiling of Melanoma and the Evolution of Patient-Specific Therapy. Seminars in Oncology, 2011, 38, 236-242.	0.8	28
112	ICAM-1 Contributes to but Is Not Essential for Tumor Antigen Cross-Priming and CD8+ T Cell-Mediated Tumor Rejection In Vivo. Journal of Immunology, 2005, 174, 3416-3420.	0.4	25
113	CD28 Is Not Required for c-Jun N-Terminal Kinase Activation in T Cells. Journal of Immunology, 2001, 167, 3123-3128.	0.4	24
114	Sensitive detection and quantification of SARS-CoV-2 in saliva. Scientific Reports, 2021, 11, 12425.	1.6	24
115	Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. , 2016, 4, 35.		21
116	Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. , 2021, 9, e002417.		21
117	The Expanding Universe of Regulatory T Cell Subsets in Cancer. Immunity, 2007, 27, 185-187.	6.6	20
118	Metabolic Mechanisms of Tumor Resistance to T Cell Effector Function. Immunologic Research, 2005, 31, 107-118.	1.3	19
119	Epigenetic Control of <i>Cdkn2a.Arf</i> Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Research, 2020, 80, 4707-4719.	0.4	19
120	Cutting Edge: Engineering Active IKKÎ² in T Cells Drives Tumor Rejection. Journal of Immunology, 2016, 196, 2933-2938.	0.4	18
121	The Microbiota: A New Variable Impacting Cancer Treatment Outcomes. Clinical Cancer Research, 2017, 23, 3229-3231.	3.2	18
122	Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance. Cell Reports, 2018, 24, 2112-2126.	2.9	17
123	PAK4 as a cancer immune-evasion target. Nature Cancer, 2020, 1, 18-19.	5.7	13
124	Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. Journal of Neuroimmunology, 2006, 174, 74-81.	1.1	12
125	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 309-317.	1.1	12
126	Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy. OncoImmunology, 2016, 5, e1116675.	2.1	9

#	Article	IF	Citations
127	Fast Forward â€" Neoadjuvant Cancer Immunotherapy. New England Journal of Medicine, 2018, 378, 2034-2035.	13.9	9
128	Back from the dead: TIL apoptosis in cancer immune evasion. British Journal of Cancer, 2018, 118, 309-311.	2.9	8
129	cDC1 dysregulation in cancer: An opportunity for intervention. Journal of Experimental Medicine, 2020, 217, .	4.2	8
130	Dietary modulation of the gut microbiome as an immunoregulatory intervention. Cancer Cell, 2022, 40, 246-248.	7.7	8
131	MYC â€" a thorn in the side of cancer immunity. Cell Research, 2016, 26, 639-640.	5.7	7
132	Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell and Melanoma Research, 2010, 23, 580-581.	1.5	6
133	Melanoma presenting as circulating tumor cells associated with failed angiogenesis. Melanoma Research, 2008, 18, 289-294.	0.6	5
134	Perspectives in melanoma: meeting report from the â€œMelanoma Bridgeâ€•(December 5thâ€"7th, 2019,) Tj ETQq0 0 0 rgBT /Overlock	1.8	5
135	Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Annals of Surgical Oncology, 2021, 28, 9039-9047.	0.7	4
136	Integrating IL-12 into therapeutic cancer vaccines. Cancer Chemotherapy and Biological Response Modifiers, 2002, 20, 343-9.	0.5	4
137	Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1. Current Opinion in Investigational Drugs, 2004, 5, 1279-83.	2.3	3
138	Primary Murine CD4+ T Cells Fail to Acquire the Ability to Produce Effector Cytokines When Active Ras Is Present during Th1/Th2 Differentiation. PLoS ONE, 2014, 9, e112831.	1.1	2
139	Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.. Blood, 2004, 104, 918-918.	0.6	2
140	Insights into Mechanisms of Immune Resistance in the Tumor Microenvironment through Molecular Profiling. , 2008, , 77-89.		1
141	Transcriptional Profiling of Melanoma as a Potential Predictive Biomarker for Response to Immunotherapy. , 2011, , 229-238.		1
142	ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients. Annals of Surgical Oncology, 2021, 28, 576-576.	0.7	0
143	Predictive Biomarkers as a Guide to Future Therapy Selection in Melanoma. , 2012, , 27-40.		0
144	Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics Tools. Biopreservation and Biobanking, 2023, 21, 166-175.	0.5	0